Viking Therapeutics to Present Data from Phase 2b VOYAGE Study ...

Corporate Presentation · Contact. News & Events. Investors. << Back. Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in ...

Viking Therapeutics Announces Positive 52-Week Histologic Data ...

News & Events. Investors. << Back. Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in ...

Viking Therapeutics to Present Key NASH Drug Trial ... - Stock Titan

Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® ...

Press Releases - Viking Therapeutics

News & Events · Nov 12, 2024. Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th ...

Viking Therapeutics Announces Positive 52-Week Histologic Data ...

Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non- ...

Viking Therapeutics Reports Positive 52-Week Data from Phase 2b ...

... data from its Phase 2b VOYAGE study. ... Report · News. Keep updated. Try Synapse. Sign Up for Free. PatSnap group products.

VK2809 Selective Thyroid Receptor-β Agonist - Viking Therapeutics

NASH and Lipid Disorders · Overview & Profile · Thyroid Hormone Receptor Overview · Clinical Data: VK2809 Phase 2b VOYAGE Study at 12 Weeks (Primary Endpoint).

Viking Therapeutics Presents New Data from Phase 2b VOYAGE ...

The latest findings from the VOYAGE study were featured in a late breaking poster presentation at the Liver Meeting® 2023, the annual ...

EX-99.1 - SEC.gov

... Phase 2 trial in patients with obesity in the fourth quarter of this year. •. Reported Positive 52-Week Histologic Data from Phase 2b VOYAGE Study Evaluating ...

Pipeline Overview - Viking Therapeutics

Phase 1 ongoing. Phase 2 planned. VK2809 (TRβ Agonist), NASH, Phase 2b VOYAGE trial recently completed. VK0214 (TRβ Agonist), X_ALD, Phase 1b study recently ...

vktx-ex991_6.htm - SEC.gov

Viking Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update · Enrollment Continues in Phase 2b VOYAGE Study Evaluating VK2809 ...

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity ...

Viking is presenting results from the Phase 2 VENTURE trial of ... Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of ...

Viking Therapeutics Reports Third Quarter 2024 Financial Results ...

Results from the VOYAGE study have been selected for oral presentation ... Results from the 52 Week Phase 2b VOYAGE Trial of VK2809 in Patients ...

Ligand's Partner Viking Therapeutics Announces Positive Top-Line ...

Ligand's Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with ...

Viking Therapeutics Announces Positive Top-Line Results from ...

Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study ... The company expects to submit the results for presentation ...

Viking Therapeutics Reports Positive 52-week Histologic Data From ...

(RTTNews) - Viking Therapeutics, Inc. (VKTX) Tuesday reported positive 52-week histologic data from its Phase 2b VOYAGE study of VK2809 in ...

Viking Therapeutics Reports New Data from VK2735 Obesity ...

Updated Results from VENTURE Phase 2 Study of Subcutaneous VK2735 Show Durable Effects and Support Potential Monthly Dosing Regimen. SAN ...

Viking Therapeutics Announces Initiation of Phase 2b VOYAGE ...

... VOYAGE study. Select data from these studies may be submitted for presentation at future scientific conferences. Viking previously announced ...

Viking Therapeutics To Present Data From Phase 2b VOYAGE ...

VikingTherapeutics To Present Data From Phase 2b VOYAGE Study Of VK2809 In Patients With Biopsy-Confirmed NASH/MASH At 75th Liver Meeting 2024.

Bertrand Delsuc - X.com

Viking Therapeutics $VKTX to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at #TLM24 ...